A GPC1-targeted and gemcitabine-loaded biocompatible nanoplatform for pancreatic cancer multimodal imaging and therapy

Biomarker-targeted nanocarrier holds promise for early diagnosis and effective therapy of cancer. This work successfully designs and evaluates GPC1-targeted, gemcitabine (GEM)-loaded multifunctional gold nanocarrier for near-infrared fluorescence (NIRF)/MRI and targeted chemotherapy against pancreatic cancer and . Blood biochemical and histological analyses show that the toxicity of GPC1-GEM-nanoparticles (NPs) was negligible. Both and studies demonstrate that GPC1-GEM-NPs can be used as NIRF/MR contrast agent for pancreatic cancer detection. Treatment of xenografted mice with GPC1-GEM-NPs shows a higher tumor inhibitory effect compared with controls. This novel theranostic nanoplatform provides early diagnostic and effective therapeutic potential for pancreatic cancer. Development and functionality of the GPC1-GEM-NPs. The preparation of GPC1-GEM-NPs. GPC1-GEM-NPs as tumor-targeted multifunctional theranostic nanoplatforms for multimodal imaging and therapy by GPC1-mediated antibody–antigen combination. Coincubation; Au–S coupling chemistry; amidation reaction; antibody–antigen combination; endocytosis; endosome escape; pH/hyaluronidase response.